Company: CERO
Filing Date: 2025-05-15
Form Type: 10-Q
Source: 0001213900-25-044335
Chunk: 2

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-05-15
Form: 10-Q
Item: Item 1
Chunk 2
---
  
    For the  Period from  January 1,  2024  through  February 13,  2024 

    (Successor)  
    (Successor)  
    (Predecessor) 
  
    Operating expenses: 

    Research and development 
    $2,907,827  
    $904,015  
    $764,192 
  
    General and administrative 
     2,042,704  
     2,750,922  
     132,941 
  
    Total operating expenses 
     4,950,531  
     3,654,937  
     897,133 
  
    Loss from operations 
     (4,950,531) 
     (3,654,937) 
     (897,133)

    Other income (expense): 

    Gain from settlement of liabilities with vendors 
     -  
     141,888  
     - 
  
    Change in fair value of earnout liability 
     -  
     1,800,000  
     320,117 
  
    Share-based inducement expense 
     (156,250) 
     -  
     - 
  
    Interest income (expense), net 
     850  
     (14,434) 
     4,805 

    Total other income (expense), net 
     (155,400) 
     1,927,454  
     324,922 
  
    Net loss 
     (5,105,931) 
     (1,727,483) 
     (572,211)
  
    Deemed dividends of Series A, B and C Preferred Stock 
     (264,144) 
     -  
     - 
  
    Deemed dividends related to Series C Common Warrants 
     (84,083) 
     -  
     - 
  
    Net loss attributable to common shareholders 
    $(5,454,158) 
    $(1,727,483) 
    $(572,211)

    Net loss per common share: 

    Basic and diluted 
    $(1.59) 
    $(12.24) 
    $(97.90)
  
    Weighted average common shares outstanding: 

    Basic and diluted 
     3,427,